<DOC>
	<DOCNO>NCT01343186</DOCNO>
	<brief_summary>This study aim study pharmacokinetic characteristic ( e.g . AUC , Cmax , Tmax ) Ypeginterferon alfa-2a interferon biomarkers ( e.g . 2,5-OAS , neopterin ) single dose different level .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Assessment Ypeginterferon Alfa-2a Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Healthy subject Age 18 45 , inclusive Body mass index ( BMI ) 19 26 , inclusive Sign inform consent Women pregnant lactation Known hypersensitivity interferon component study drug History mental disease genetic disease History diabetes mellitus , thyroid disease , cancer , autoimmune disease , organ transplant Significant disease heart , liver , kidney , lung major organ Alcoholic , smoker drug abuser Blood donation , massive blood loss due injury surgery within 3 month Other condition opinion investigator preclude enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Peginterferon</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Safety</keyword>
</DOC>